Lung Cancer Trials Ask AI to find trials
TerminatedPhase 2NCT02750514
Official study title

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

Study summary

The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedNivolumab and Dasatinib

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 22, 2021 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?50 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 2
Sponsor
Bristol-Myers Squibb
Interventions being studied
Biological: Nivolumab; Drug: Dasatinib; Biological: Relatlimab; Biological: Ipilimumab; Drug: BMS-986205
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
  • Advanced Non Small Cell Lung Cancer (NSCLC)
  • Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1
  • Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment
  • Must have at least 1 lesion with measurable disease
Reasons someone may not be able to joinExclusion criteria
  • Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment
  • Subjects who need daily oxygen therapy
  • People with autoimmune disease Other protocol defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • City of Hope National Medical CenterDuarte, California
  • University of Southern California (USC)Los Angeles, California
  • Cedars-Sinai Medical CenterLos Angeles, California
  • University of Californa, Los Angeles (UCLA)Los Angeles, California
  • Hoag Memorial Hospital PresbyterianNewport Beach, California
  • University of California San DiegoSan Diego, California
  • University of Colorado DenverAurora, Colorado
  • Yale Cancer CenterNew Haven, Connecticut
  • University of Kansas Cancer CenterWestwood, Kansas
  • University of Maryland - Marlene and Stewart Greenebaum Cancer CenterBaltimore, Maryland
  • Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland
  • Massachusetts General HospitalBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 22, 2021. Always confirm current availability with the study team.

View original record ↗